Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model-Reference-Cited by-同舟云学术

Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model

Published:2020 Issue:22 Volume:8 Page:6246-6260
ISSN:2047-4830
Container-title:Biomaterials Science
language:en
Short-container-title:Biomater. Sci.

Author:

Rodrigo M. J.¹²³⁴⁵^ORCID,Cardiel M. J.⁶⁷⁸⁴⁹^ORCID,Fraile J. M.¹⁰¹¹¹²¹³⁴^ORCID,Mendez-Martinez S.¹²³⁴⁵^ORCID,Martinez-Rincon T.¹²³⁴⁵,Subias M.¹²³⁴⁵^ORCID,Polo V.¹²³⁴⁵,Ruberte J.¹⁴⁴¹⁵¹⁶¹⁷,Ramirez T.⁶⁷⁸⁴⁹,Vispe E.¹⁸¹⁰¹¹¹²³,Luna C.⁶⁷⁸⁴¹⁸,Mayoral J. A.¹⁰¹¹¹²¹³⁴,Garcia-Martin E.¹²³⁴⁵

Affiliation:

1. Department of Ophthalmology

2. Miguel Servet University Hospital

3. Zaragoza

4. Spain

5. Aragon Institute for Health Research (IIS Aragon)

6. Miguel Servet Ophthalmology Research Group (GIMSO)

7. Aragon Health Research Institute (IIS Aragon)

8. University of Zaragoza

9. Department of Pathology

10. Institute for Chemical Synthesis and Homogeneous Catalysis (ISQCH)

11. Faculty of Sciences

12. University of Zaragoza-CSIC

13. E-50009 Zaragoza

14. RETICS: Thematic Networks for Co-operative Research in Health for Ocular Diseases

15. Centre for Animal Biotechnology and Gene Therapy (CBATEG)

16. Universitat Autònoma de Barcelona

17. Bellaterra

18. Chromatography and Spectroscopy Laboratory

Abstract

Brimonidine-LAPONITE® formulation is a potential intravitreal formulation for glaucoma treatment. It exhibits an early ocular hypotensive effect and functional and structural neuroretinal protection over 24 weeks of follow-up, after single injection.

Funder

Ministerio de Ciencia e Innovación

Instituto de Salud Carlos III

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering

Link

http://pubs.rsc.org/en/content/articlepdf/2020/BM/D0BM01013H

Reference86 articles.

1. Glaucoma

2. The molecular basis of retinal ganglion cell death in glaucoma